There is a new list of reimbursed drugs. Favorable changes for patients

The new list of reimbursed drugs will come into force on September 1, 2022. Medicines are returned by 30 percent. payment for the patient. The Ministry of Health expects possible comments on the draft announcement in the electronic version until August 18, 2022 at 12.00.

What is a return?

Compensation gives you the opportunity to purchase medical products at a lower price and includes:

• essential prescription drugs and prescription drugs,

• products for special nutrition,

• medical products.

In case of reimbursement, part of the costs for the purchase of the above medical devices is covered by the National Health Fund; the list of reimbursed drugs and the level of reimbursement are established by the Ministry of Health.

Beneficial changes for diabetics

Antidiabetic inhibitors will be reimbursed DPP-4 for oral use in combination with metformin in type 2 diabetes mellitus:

• Galvus (vildagliptin),

• Januvia (sitagliptin),

• Janumet (sitagliptin + metformin hydrochloride).

Changes for patients with drug-resistant tuberculosis

The program funds two drug-resistant TB drug treatments:

• A. bedaquiline (Sirturo) in combination with anti-tuberculosis drugs (MDR-TB pulmonary tuberculosis);

• B. pretomanid (Dovprela) in combination with bedaquiline and linezolid (MDR-TB or XDR-TB pulmonary tuberculosis).

A drug program may qualify a patient for therapy 1 or 2. The above therapies cannot be considered as a line of treatment.

Changes for patients with acute myeloid leukemia:

• Xospata (gilteritinib)

• Mylotarg (Gemtuzumab ozogamicin)

Venclyxto (venetoclax) will also be funded under program B.114 (while being reimbursed under program B.103 - treatment of patients with chronic lymphocytic leukemia with venetoclax).

After the changes, the drug treatment program for acute myeloid leukemia is as follows:

A. in the first line of treatment:

1. treatment with midostaurin in combination with daunorubicin and cytarabine (patients with FLT3 mutation),

2. treatment with gemtuzumab ozogamicin in combination with daunorubicin and cytarabine (regardless of FLT3 mutation status),

3. venetoclax in combination with azacitidine (regardless of FLT3 mutation status).

B. in the second and subsequent lines of treatment:

1. treatment with vineritinib as monotherapy (patients with FLT3 mutation).